Graham Capital Management L.P. Has $267,000 Stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Graham Capital Management L.P. decreased its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 18.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,200 shares of the biopharmaceutical company’s stock after selling 737 shares during the period. Graham Capital Management L.P.’s holdings in Intra-Cellular Therapies were worth $267,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its position in shares of Intra-Cellular Therapies by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 22,480 shares of the biopharmaceutical company’s stock worth $1,878,000 after purchasing an additional 2,157 shares during the period. Barclays PLC raised its position in shares of Intra-Cellular Therapies by 282.0% during the third quarter. Barclays PLC now owns 34,453 shares of the biopharmaceutical company’s stock worth $2,521,000 after purchasing an additional 25,435 shares during the period. Oak Ridge Investments LLC raised its position in shares of Intra-Cellular Therapies by 74.1% during the fourth quarter. Oak Ridge Investments LLC now owns 19,831 shares of the biopharmaceutical company’s stock worth $1,656,000 after purchasing an additional 8,440 shares during the period. Merit Financial Group LLC acquired a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $206,000. Finally, SG Americas Securities LLC raised its position in shares of Intra-Cellular Therapies by 204.4% during the fourth quarter. SG Americas Securities LLC now owns 12,917 shares of the biopharmaceutical company’s stock worth $1,079,000 after purchasing an additional 8,673 shares during the period. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Performance

NASDAQ:ITCI opened at $131.87 on Friday. The company has a market cap of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.98. The stock has a 50-day simple moving average of $131.79 and a 200 day simple moving average of $114.01.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million during the quarter, compared to the consensus estimate of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, research analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ITCI has been the topic of a number of research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $140.00 to $132.00 in a research report on Monday, February 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $132.00 price target on shares of Intra-Cellular Therapies in a research report on Wednesday, April 2nd. StockNews.com began coverage on Intra-Cellular Therapies in a report on Thursday. They set a “hold” rating for the company. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $132.00 price objective (up from $108.00) on shares of Intra-Cellular Therapies in a report on Wednesday, January 22nd. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, Intra-Cellular Therapies presently has an average rating of “Hold” and a consensus price target of $109.70.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.